ClinicalTrials.gov

History of Changes for Study: NCT05259943
Microdosing Psychedelics to Improve Mood
Latest version (submitted March 28, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 25, 2022 None (earliest Version on record)
2 March 28, 2022 Study Status and Contacts/Locations
Comparison Format:

Scroll up to access the controls

Study NCT05259943
Submitted Date:  February 25, 2022 (v1)

Open or close this module Study Identification
Unique Protocol ID: ABC123DRM
Brief Title: Microdosing Psychedelics to Improve Mood
Official Title: Microdosing Psychedelics to Improve Mood
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2022
Overall Status: Not yet recruiting
Study Start: April 2022
Primary Completion: April 2023 [Anticipated]
Study Completion: August 2023 [Anticipated]
First Submitted: February 15, 2022
First Submitted that
Met QC Criteria:
February 25, 2022
First Posted: March 2, 2022 [Actual]
Last Update Submitted that
Met QC Criteria:
February 25, 2022
Last Update Posted: March 2, 2022 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Rotem Petranker
Responsible Party: Sponsor-Investigator
Investigator: Rotem Petranker
Official Title: Associate Director, Psychedelic Studies Research Program
Affiliation: University of Toronto
Collaborators: Nikean Foundation
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The purpose of this trial is to examine the safety and efficacy of small (2mg) sub hallucinogenic doses of psilocybin in people with Persistent Depressive Disorder.
Detailed Description: This protocol is for a University of Toronto - sponsored, randomized, placebo-controlled crossover phase 2 study of the safety and efficacy of low doses of psilocybin in subjects with depressive symptoms who meet Diagnostic and Statistical Manual 5 (DSM-5) criteria for diagnosis of a persistent depressive disorder (PDD) with pure dysthymic syndrome and who are either unwilling to pursue standard treatment (psychotherapy and/or pharmacotherapy) or have previously been non-responsive to standard treatment. This feasibility study will assess whether microdosing has a short-term impact on participant ratings of depressive symptoms. Participants will be administered one dose of either placebo or psilocybin once weekly for four weeks, and then all participants will be administered a dose of psilocybin once weekly for four additional weeks. Short surveys will be collected once weekly three days after the administration of psilocybin/placebo, and follow-ups will occur for up to two years following the beginning of the trial. Using this design will maximize the experimental power to detect an effect if one exists and would inform future research on microdosing in terms of duration, effect size, and expectancy bias.
Open or close this module Conditions
Conditions: Persistent Depressive Disorder, Dysthymia
Keywords: Psilocybin
Psychedelics
Creativity
Mindfulness
Depression
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Crossover Assignment
This trial starts as a placebo-control for 4 weeks and then becomes Open Label for 4 additional weeks. Follow-up assessments will be performed weekly for the first 4 weeks following the last Open Label week.
Number of Arms: 3
Masking: Triple (Participant, Care Provider, Investigator)
Allocation: Randomized
Enrollment: 50 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Placebo Comparator: Blinded Placebo
In this condition participants will receive an inert placebo once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
Drug: Placebo first
Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
Experimental: Blinded Psilocybin
In this condition participants will receive psilocybin once weekly for 4 weeks, but they will not know whether they receive placebo or psilocybin.
Drug: Psilocybin first
Participants will receive 8 doses of 2mg psilocybin.
Experimental: Open Label
In this condition participants will receive psilocybin once weekly for 4 weeks, and will be told that they are receiving psilocybin.
Drug: Psilocybin first
Participants will receive 8 doses of 2mg psilocybin.
Drug: Placebo first
Participants will receive 4 doses of placebo followed by 4 doses of 2mg psilocybin
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Change in Cornell Dysthymia Rating Scale (CDRS)
[ Time Frame: Weeks 1, 3, and 7. Additional follow-up on weeks 11 and 13. ]

The CDRS is based on the Hamilton Depression Rating Scale but is oriented towards episodic rather than chronic states of depression. It contains 20 items on which participants can be rated between 0 (symptom absent) and 4 (severe symptoms). This scale aims to assess symptomatology with a finer grain for those whose symptoms may be milder (Cohen, 1997). Subsequent research supports the notion that this scale has better construct validity for those suffering from persistent depressive disorder (Hellerstein et al., 2002).
Secondary Outcome Measures:
1. Change in Patient Health Questionnaire Somatic-Anxiety-Depression
[ Time Frame: Every week until week 14. ]

The PHQ-SADS is a 32-item self-report subset of the full PHQ designed to detect the co-occurrence of somatic, anxiety, and depressive symptoms (the SAD triad). Responses are measured using a likert scale between 0 (not bothered) and 2 (bothered a lot). Higher scores suggest more severe depressive symptoms.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age: 65 Years
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

Participants must:

  • Have given written informed consent.
  • Have a high school level of education.
  • Be fluent in speaking and reading the predominantly used or recognized language of the study site (i.e. English).
  • Be 18 to 65 years old.
  • If of childbearing potential, must have a negative pregnancy test at study entry and must agree to use adequate birth control through 10 days after the last Experimental Session (refer to section 9.4.2 for contraceptive guidelines).
  • Have a preexisting diagnosis of PDD with dysthymic subtype or receive a diagnosis of PDD with dysthymic subtype during screening.
  • Agree that for one week preceding each psilocybin session, they will refrain from taking any nonprescription medication, nutritional supplements, or herbal supplement except when approved by the research team. Exceptions will be evaluated by the research team and will include acetaminophen, non-steroidal anti-inflammatory drugs, and common doses of vitamins and minerals with the exception of SAM-e, 5-HTP, L-tryptophan, and St. John's Wort.
  • Agree to consume approximately the same amount of caffeine-containing beverage (i.e. coffee, tea) that they consume on a usual morning, before arriving at the research unit on the mornings of psilocybin session days. Caffeine consumption should not exceed more than ≥600mg/day. If the patient does not routinely consume caffeinated beverages, they must agree not to do so on psilocybin session days.
  • Agree not to take any as needed (PRN) medications on the mornings of psilocybin sessions. Non-routine PRN medications for treating breakthrough pain that were taken in the 24 hours before the psilocybin session may result in rescheduling the treatment session, with the decision at the discretion of the investigators.
  • Agree to refrain from using any psychoactive drugs, including alcoholic beverages, within 24 hours of each psilocybin administration. As described elsewhere, exceptions include daily use of caffeine.

Exclusion Criteria:

  • The subject has participated in another investigational study within 60 days prior to the screening visit.
  • Cardiovascular conditions: coronary artery disease, uncontrolled hypertension, angina, a clinically significant ECG abnormality (i.e. atrial fibrillation), TIA in the last 6 months, stroke, peripheral or pulmonary vascular disease (no active claudication).
  • Blood pressure exceeding screening criteria described below:

    ○ Cardiovascular screening:

    • At the screening and randomization visit, blood pressure will be assessed to qualify to proceed in the trial. Each assessment occasion will involve two or more blood pressure readings. To qualify for the study, the mean blood pressure (mmHg) of the two readings will not exceed 140 systolic and 90 diastolic.
    • Blood pressure (BP) will be taken while subjects are at rest and have been seated or supine for at least 5 minutes. The assessment will involve the average of 2 or more readings separated by fifteen minutes. If the first 2 readings differ by more than 5 mmHg, additional readings will be obtained and averaged. During the BP assessment, the volunteer will be acclimated to the automated blood pressure monitoring equipment by repeatedly taking blood pressure (at least 3 readings) with the device.
  • Epilepsy with a history of seizures.
  • The subject has a history of cerebral ischemia, transient ischemic attack, intracranial aneurysm, or arteriovenous malformation.
  • The subject has a clinically significant history of head injury or head trauma per the judgement of the investigator.
  • The subject has a history of cancer.
  • Unstable medical condition, severe renal disease (creatinine clearance < 40 ml/min using the Cockcroft and Gault equation), hepatic disease (known history of liver disease, abnormal elevations in LFTs), or serious central nervous system pathology.
  • Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia.
  • Are pregnant (positive urine pregnancy test assessed at screening) or nursing, or are of childbearing potential and are not practicing an effective means of birth control (refer to section 9.4.2 for contraceptive guidelines).
  • Currently taking on a regular (i.e. daily) basis any psychotropic medications including: investigational agents, psychoactive prescription medications (i.e. benzodiazepines), antidepressants, medications having a primary pharmacological effect on serotonin neurons (i.e. ondansetron), medications that are MAO inhibitors, opioid medications. If previously on antidepressants a minimum of five half lives must have passed from the last dose of medication plus an additional seven days of stabilization before first administration of the drug.
  • Current use of any the following of potent metabolic inducers or inhibitors: Inducers - Rifamycin (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, Phenobarbital), Nevirapine, Efavirenz, Taxol, Dexamethasone), St John's Wort; All cytochrome P450 Inhibitors - including all HIV protease inhibitors, verapamil, diltiazem, itraconazole, ketoconazole, erythromycin, clarithromycin, azithromycin, and troleandomycin.
  • Use of steroids within the past two weeks.
  • Current use of the following drugs will also meet exclusion criteria: ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl.
  • Agree to refrain from using any psychoactive drugs, including alcoholic beverages within 24 hours of each drug administration. The exception is caffeine.
  • Must not be a habitual smoker.
  • Refrain from starting any new medications.
  • Refrain from starting any new complementary or alternative medicine practices (i.e. nutrition/diet modifications, supplements, meditation practice, etc.).
  • Are willing to comply with medication requirements per the protocol (refer to Section 6.2).
  • Lifestyle Criteria; Refrain from working night shifts.

Psychiatric Exclusion Criteria:

  • Current or past history of meeting DSM-V criteria for Schizophrenia, Psychotic Disorder, or Bipolar I or II Disorder.
  • Active Major Depressive Disorder Episode.
  • Having a first or second degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or bipolar I or II disorder.
  • Currently meets DSM-V criteria for Dissociative Disorder, Anorexia Nervosa, Bulimia Nervosa, or other psychiatric conditions judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
  • Current or past history within the last 5 years of meeting DSM-V criteria for a moderate or severe alcohol or drug use disorder (excluding caffeine and nicotine).
  • Use within 6 months of psychedelic substances.
Open or close this module Contacts/Locations
Central Contact Person: Rotem Petranker
Telephone: 6479376234
Email: rotem@petranker.com
Locations: Canada, Ontario
Psych Research
Toronto, Ontario, Canada, M5C 1N8
Contact:Contact: Adam Blackman, M.D. adam@mettascience.com
Open or close this module IPDSharing
Plan to Share IPD: Undecided
We will pre-register our study and we will make our data available. Whether IPD will be available is TBD.
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services